Keywords: analyst, considers, impact, loss, accutane, patent, roche

Analyst considers impact that loss of US Accutane patent will have on Roche

Article | 04 February 2002

Print This

On February 7, a key US patent on Roche's acne treatment Accutane(isotretinoin) expires. With sales of about $700 million a year, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in